JQEZ5

CI-DRUG-00000322Explore in graph →CHEMBL4545488 CIViC

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Data not yet available

No registered interventional trial or approval record places this drug in the pipeline yet.

Curated evidence

Clinical evidence (4)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–4 of 4 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EZH2 Y646F1
JQEZ5	B-Cell Malignant Neoplasm

Clinical trials

Trials with this intervention (0)

Data not yet available

No registered study lists this drug as an intervention yet.

BRAF V600E + EZH2 Y646FEZH2 BRAF1
JQEZ5	Melanoma	Predictive	D	Supports Sensitivity Response	4	accepted	EID6952 Experiment with immunodeficient mice transplanted with melanoma cell lines indicates EZH2 inhibitor JQEZ5 might be effective in combination with a B-RAF inhibitor in RAF-mutant melanoma. PMID 27135738 · Souroullas et al., 2016 · Open in CIViC	civic

EZH2 Y6461
Dabrafenib + GSK126 + JQEZ5 + UNC1999Combination	Melanoma	Predictive	D	Supports Sensitivity Response	5	rejected	EID5677 Additional diseases: GC-DLBCL, Follicular lymphoma (FL). Y641 mutations are present in about 20% of GC-DLBCL, 10% FL, and 5% Melanoma (from TCGA/cBioportal). Also note that Y641 and Y646 mutations ar… (full text at CIViC) PMID 27135738 · Souroullas et al., 2016 · Open in CIViC	civic

MYCN Amplification1
GSK126 + JQEZ5Substitutes	Neuroblastoma	Predictive	D	Supports Sensitivity Response	3	submitted	EID6020 In a genome-scale CRISPR-Cas9 screening of MYCN-amplified neuroblastoma dependency on genes encoding the polycomb repressive complex 2 (PRC2) components EZH2, EED, and SUZ12 was identified. Genetic an… (full text at CIViC) PMID 29202477 · Chen et al., 2018 · Open in CIViC	civic